Infusion Reaction and Emergency Unblinding
During a phase III double-blind trial of an intravenous monoclonal antibody for severe asthma, Subject 2117 develops stridor, diffuse urticaria, and hypotension (82/50 mmHg) about 10 minutes into the first infusion. The investigator gives intramuscular epinephrine, stops the infusion, and starts oxygen and fluids. The subject stabilizes. The protocol provides an emergency unblinding system through the interactive voice response system and states that unblinding should occur only when knowledge of treatment assignment is necessary for the subject's clinical management. The investigator says, 'Break the blind now - I need to know if this was drug or placebo.' The coordinator also must report the event to the sponsor within 24 hours and to the IRB within 5 working days. The subject's spouse asks whether the infusion was 'the real drug.'
1. Should the coordinator break the blind immediately because the investigator asks?
Read the worked answer
The coordinator should not automatically break the blind because the investigator is curious. Emergency unblinding is justified only when knowledge of assignment is needed to manage the subject's care. Anaphylaxis after an infusion is treated the same way regardless of assignment: stop the infusion, give epinephrine, support airway and blood pressure, and observe. The investigator may still decide that knowing is necessary, for example to guide re-exposure or corticosteroid planning, but the decision and rationale must be documented. If unblinding is used, follow the protocol's interactive voice response system process and disclose the code only to clinicians who need it; do not announce it to the whole team or the spouse. The coordinator should not open a sealed envelope unless that is the protocol's specified method. Record the time, reason, person unblinded, and who was informed. Protect the blind for other participants and staff.
2. What reporting steps are required, and when does the clock start?
Read the worked answer
Report the event as a serious adverse event to the sponsor within 24 hours of the site's awareness, using the initial serious adverse event form with the information available. Do not wait for unblinding or for the final diagnosis. Include onset time, infusion start, signs (stridor, urticaria, 82/50 mmHg), treatment (epinephrine, fluids, oxygen), outcome, concomitant medications, and whether the blind was broken. Send follow-up reports as the subject's course evolves. Notify the IRB within its required 5 working days per the site's policy, and notify the medical monitor. In the source record, document the event, stop time, interventions, and reporting dates. If the subject is withdrawn, document that. The coordinator should not speculate in the serious adverse event narrative about causality; the investigator makes that assessment. The reporting clock starts at awareness, not at unblinding.
3. What should the coordinator tell the spouse about treatment assignment?
Read the worked answer
Tell the spouse that the study team cannot confirm treatment assignment because the trial is blinded and doing so could affect the study, but that the immediate medical care is the same either way. If the investigator has unblinded for clinical management, the PI should decide what, if anything, to disclose to the subject and spouse, and the discussion should be documented. Do not guess or say 'it was probably the drug.' Answer questions about the reaction, follow-up, and reporting process in plain language. Ask the subject to report recurrent symptoms. If disclosure of assignment is needed for future care, coordinate with the PI and sponsor. The coordinator should protect confidentiality and avoid discussing the case in public areas. Empathy and clear next steps matter, but speculation about assignment is not appropriate.